Cyclerion Therapeutics Inc
1.18 - 1.37
1.18 - 6.9
Join Discuss about CYCN with like-minded investors
Upside: -CYCN +16% (announces Global Licensing agreement with Akebia Therapeutics for Praliciguat; eligible to receive up to $585M in milestone payments) -SFIX +12% (earnings, guidance) -REVG +10% (earnings, guidance) -CHS +9.9% (earnings, guidance) -EVOK +8.4% (announces FDA Orange Book Listing of U.S. Patent for Gimoti) -ASO +7.2% (earnings, guidance) -MCF +6.6% (to be acquired by Independence Energy in all stock transaction valued at ~$5.7B) -JILL +6.3% (earnings, guidance) -MRVL +5.6% (earnings, guidance) -BYSI +4.8% (announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data) -THO +4.1% (earnings) -STX +3.7% (raises guidance) -TSLA +2.9% (strong China May passenger vehicle sales) -INO +2.6% (expands partnership with Advaccine to conduct global Phase III efficacy trial of COVID-19 DNA vaccine candidate, INO-4800) -OTLK +2.3% (reports completion of patient dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial) -FTCI +1.4% (earnings, guidance; raising prices) -LUV +1.2% (guidance) Downside: -PLBY -10% (files to offer 4.0M shares) -COUP -8.9% (earnings, guidance; Tony Tiscornia promoted to CFO) -TIGR -7.6% (files to sell 6.5M ADS) -HSTO -7.5% (announces 6.0M share direct offering priced at $1.10/shr) -LESL -5.7% (to sell 24.5M shares for holders) -HQY -5.5% (earnings, guidance) -KDP -4.9% (files to sell 28M common share secondary offering on behalf of Mondelez International) -FTCI -4.7% (earnings, guidance; raising prices) -FSLY -1.7% (hearing Fastly edge CDN platform is having issues causing internet outages) -ETSY -1.3% (files proposed private offering of $1.0B of convertible senior notes) -WBA -1.3% (AMZN reportedly to offer discounted pharmacy services targeting uninsured and those paying cash)
124 Replies 6 👍 6 🔥
Next Dividend Date
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive impairment and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).